Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

If You Use a Screen Reader

This content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.

HER2YVMA Drives Rapid Development of Adenosquamous Lung Tumors in Mice That Are Sensitive to BIBW2992 and Rapamycin Combination Therapy

Samanthi A. Perera, Danan Li, Takeshi Shimamura, Maria G. Raso, Hongbin Ji, Liang Chen, Christa L. Borgman, Sara Zaghlul, Kathleyn A. Brandstetter, Shigeto Kubo, Masaya Takahashi, Lucian R. Chirieac, Robert F. Padera, Roderick T. Branson, Geoffrey I. Shapiro, Heidi Greulich, Matthew Meyerson, Ulrich Guertler, Pilar Garin Chesa, Flavio Solca, Ignacio I. Wistuba, Kwok-Kin Wong and Webster K. Cavenee
Proceedings of the National Academy of Sciences of the United States of America
Vol. 106, No. 2 (Jan. 13, 2009), pp. 474-479
Stable URL: http://www.jstor.org/stable/40254804
Page Count: 6
  • Read Online (Free)
  • Subscribe ($19.50)
  • Cite this Item
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
HER2YVMA Drives Rapid Development of Adenosquamous Lung
                            Tumors in Mice That Are Sensitive to BIBW2992 and Rapamycin Combination
                            Therapy
Preview not available

Abstract

Mutations in the HER2 kinase domain have been identified in human clinical lung cancer specimens. Here we demonstrate that inducible expression of the most common HER2 mutant HER2YVMA in mouse lung epithelium causes invasive adenosquamous carcinomas restricted to proximal and distal bronchioles. Continuous expression of HER2YVMA is essential for tumor maintenance, suggesting a key role for HER2 in lung adenosquamous tumorigenesis. Preclinical studies assessing the in vivo effect of erlotinib, trastuzumab, BIBW2992, and/or rapamycin on HER2YVMA transgenic mice or H1781 xenografts with documented tumor burden revealed that the combination of BIBW2992 and rapamycin is the most effective treatment paradigm causing significant tumor shrinkage. Immunohistochemical analysis of lung tumors treated with BIBW2992 and rapamycin combination revealed decreased phosphorylation levels for proteins in both upstream and downstream arms of MAPK and Akt/mTOR signaling axes, indicating inhibition of these pathways. Based on these findings, clinical testing of the BIBW2992/rapamycin combination in non-small cell lung cancer patients with tumors expressing HER2 mutations is warranted.

Page Thumbnails

  • Thumbnail: Page 
474
    474
  • Thumbnail: Page 
475
    475
  • Thumbnail: Page 
476
    476
  • Thumbnail: Page 
477
    477
  • Thumbnail: Page 
478
    478
  • Thumbnail: Page 
479
    479